Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Kalendar
Skriner
Yangiliklar
Biz haqimizda

BIO - Bio-Rad Laboratories, Inc. So'nggi... | Finranks

Home

/

BIO

B

Bio-Rad Laboratories, Inc. (BIO)

NYQ – Real vaqt narxi. Valyuta: USD

362.33

+6.08 (1.71%)

Yopilishda: Aug 12, 2026, 4:00 PM EDT

362.08

-0.25 (-0.07%)

Bozordan keyin: Aug 12, 2026, 4:04 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Don't Overlook Bio-Rad (BIO) International Revenue Trends While Assessing the Stock

Don't Overlook Bio-Rad (BIO) International Revenue Trends While Assessing the Stock

Explore Bio-Rad's (BIO) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

Bio-Rad Laboratories Q2 Earnings Call Highlights

Bio-Rad Laboratories Q2 Earnings Call Highlights

Bio-Rad Laboratories NYSE: BIO reported second-quarter revenue of approximately $651 million, essentially flat from $652 million a year earlier on a reported basis and down 1.9% on a currency-neutral basis, as continued softness in academic research markets weighed on its Life Science segment.

Bio-Rad Laboratories, Inc. (BIO) Q2 2026 Earnings Call Transcript

Bio-Rad Laboratories, Inc. (BIO) Q2 2026 Earnings Call Transcript

Bio-Rad Laboratories, Inc. (BIO) Q2 2026 Earnings Call Transcript

Bio-Rad Laboratories (BIO) Beats Q2 Earnings Estimates

Bio-Rad Laboratories (BIO) Beats Q2 Earnings Estimates

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.62 per share, beating the Zacks Consensus Estimate of $2.34 per share. This compares to earnings of $2.61 per share a year ago.

Bio-Rad Reports Second-Quarter 2026 Financial Results

Bio-Rad Reports Second-Quarter 2026 Financial Results

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June 30, 2026. Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer, stated: “Second-quarter reported revenue was flat year-over-year, with growth in Clinical Diagnostics offset by continued softness in Life Science. Despite Life Science headwinds, our digital PCR.

Videolar

No Data

There is no data to display

Press-relizlar

Bio-Rad Reports Second-Quarter 2026 Financial Results

Bio-Rad Reports Second-Quarter 2026 Financial Results

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June 30, 2026. Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer, stated: “Second-quarter reported revenue was flat year-over-year, with growth in Clinical Diagnostics offset by continued softness in Life Science. Despite Life Science headwinds, our digital PCR.